Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.96 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807350 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CYP2A13POLBKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7409874 | 0.96 | ALDH1A1 (0.96) | ALDH1A1CYP2A13POLBKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL23850789 | 0.94 | ALDH1A1 (0.85) | ALDH1A1CYP2A13POLBKDM4ESMN1; SMN2 | |
| SCHEMBL16226380 | 0.91 | ALDH1A1 (0.81) | ALDH1A1CYP2A13POLBKDM4ESMN1; SMN2 | |
| SCHEMBL14614566 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CYP2A13POLBKDM4ESMN1; SMN2 | |
| SCHEMBL2096803 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CYP2A13POLBKDM4ESMN1; SMN2 | |
| SCHEMBL11196594 | 0.84 | ALDH1A1 (0.69) | ALDH1A1POLBKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL6803849 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CYP2A13POLBKDM4ESMN1; SMN2 | |
| SCHEMBL8803732 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CYP2A13POLBKDM4EKMT2A | |
| SCHEMBL7424299 | 0.83 | ALDH1A1 (0.68) | ALDH1A1CYP2A13POLBKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020047312-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| CN-106661017-B | Bicyclic or tricyclic heterocyclic compounds | 田边三菱制药株式会社 | 2019-09-24 | — | — | CN | disclosed |
| WO-2017201468-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | WO | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-4853470-A | 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | ALDH1A1 3113/4885CYP2A13 3240/4885POLB 4435/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | ALDH1A1 3113/4885CYP2A13 3240/4885POLB 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.